Mr. Speaker, the member made an important comment. Further examination is required as to what has taken place within the industry. Suggestions have been made that some of the shortages have to do with the fact that companies are downplaying the cheaper generics or putting them out of production in favour of much more expensive newer drugs under the generic cover. This could be exacerbated through the comprehensive economic and trade agreement, CETA, that is being negotiated with the European Union. There are many concerns that it would raise the cost of generic drugs. It is a complex issue and it does require examination.
Let us deal with the crisis right now. Let us also examine how to get control over what is happening in this very powerful market to make sure that the needs of Canadians for pain medications and medications in general come first.